42
Participants
Start Date
August 31, 2004
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2009
Docetaxel
Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
Bevacizumab
Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Collaborators (2)
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Genentech, Inc.
INDUSTRY
Sanofi
INDUSTRY
Dana-Farber Cancer Institute
OTHER